SCHEMBL30765463

SCHEMBL30765463

CCCCOC(=O)Cn1c(-c2ccc(OC3CS(=O)(=O)C3)cc2)ncc(NCCCc2ccccc2)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ELANE P08246 11/20 0.38
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
LMNA P02545 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
AVPR1B P47901 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
ADORA2B P29275 1/20 0.35
ALDH1A1 P00352 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ASPH Q12797 1/20 0.34
RIOX2 Q8IUF8 1/20 0.34
KDM8 Q8N371 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765905 0.89 ELANE (0.39) ELANENPC1RAB9AAVPR1BKDM4E
SCHEMBL30766090 0.89 ELANE (0.39) ELANEAVPR1BALDH1A1KDM4EASPH
SCHEMBL30765613 0.86 GAA (0.50) GAAL3MBTL1ELANEMEN1KMT2A
SCHEMBL30765608 0.84 GAA (0.41) GAAL3MBTL1ELANEMEN1KMT2A
SCHEMBL30766150 0.84 GAA (0.52) GAAL3MBTL1ELANEMEN1KMT2A
SCHEMBL30765638 0.83 GAA (0.41) GAAL3MBTL1ELANEADORA3ADORA2B
SCHEMBL30765630 0.83 GAA (0.47) GAAL3MBTL1ELANEMEN1KMT2A
SCHEMBL30765524 0.81 GAA (0.44) GAAL3MBTL1ELANEMEN1KMT2A
SCHEMBL30765667 0.80 GAA (0.56) GAAL3MBTL1ELANEMEN1KMT2A
SCHEMBL30765659 0.79 ELANE (0.39) ELANENPC1RAB9AKDM4EASPH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed